A systematic review of extraneural meningioma metastasis: timing, evolution and outlook
Purpose Extraneural meningioma metastasis is a rare occurrence and may pose a clinical challenge due to its unclear prognosis. In this systematic review, we analyze patient demographics, clinical characteristics, management strategies, and outcomes. Methods PubMed, EMBASE, Scopus, Cochrane, and Web...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2024-06, Vol.168 (2), p.187-196 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 196 |
|---|---|
| container_issue | 2 |
| container_start_page | 187 |
| container_title | Journal of neuro-oncology |
| container_volume | 168 |
| creator | Watanabe, Gina Young, Kurtis Rauber, Erin Khan, Mohammad Faizan Suzuki, Reannon Riestenberg, Robert Umana, Giuseppe E. Palmisciano, Paolo |
| description | Purpose
Extraneural meningioma metastasis is a rare occurrence and may pose a clinical challenge due to its unclear prognosis. In this systematic review, we analyze patient demographics, clinical characteristics, management strategies, and outcomes.
Methods
PubMed, EMBASE, Scopus, Cochrane, and Web of Science databases were searched from inception to February 23, 2024 for cases of metastatic meningioma according to PRISMA guidelines. Descriptive statistics, Mann–Whitney U test, Fisher's exact tests, Kaplan–Meier curves, and log-rank tests were used for selected analyses.
Results
A total of 288 patients (52% male) were included with an average age of 49 years at meningioma diagnosis. Tumors were distributed across WHO grade 1 (38%), 2 (36%), and 3 (26%). Most patients experienced intracranial recurrence (79%) and mean time to first metastasis was approximately 8 years. No change in WHO grade between primary and metastasis was observed for most cases (65%). Treatment of the initial metastasis was most often with surgery (43%), chemotherapy (20%), or no treatment (14%). Half of the patients were alive (50%) with an average follow-up of 3 years following metastasis. Overall median survival was 36 months for the entire cohort. This differed significantly between WHO grade 1 versus 2/3 meningioma primaries (168 vs. 15 months, p |
| doi_str_mv | 10.1007/s11060-024-04659-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3003439841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3003439841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-148d17ac0ccc7a9166f89d8895861e52ac3445318f84247d50c782180be22b663</originalsourceid><addsrcrecordid>eNp9kE1rFTEUhoNU7G31D7goATdddPTkO3FXLtoKBTeK7kJuJlPSzkzaJNPaf2-ut1ZwUQgkJE_e8_Ig9JbAewKgPhRCQEIHlHfApTCdfIFWRCjWKabYHloBkaoThv_cRwelXAEAV4y8QvtMCwaCmxX6cYrLQ6lhcjV6nMNdDPc4DTj8qtnNYcluxFOY43wZ0-TasbrSViwfcY1Tuz7B4S6NS41pxm7ucVrqmNL1a_RycGMJbx73Q_T986dv6_Pu4uvZl_XpRecZlbUjXPdEOQ_ee-UMkXLQptfaCC1JENR5xrlgRA-aU656AV5pSjRsAqUbKdkhOt7l3uR0u4RS7RSLD-PYyqelWAbAODOak4a--w-9SkueW7tGSWaoJMI0iu4on1MpOQz2JsfJ5QdLwG61251227TbP9rttsXRY_SymUL_9OWv5wawHVDa03wZ8r_Zz8T-Bt9CjJs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3063926159</pqid></control><display><type>article</type><title>A systematic review of extraneural meningioma metastasis: timing, evolution and outlook</title><source>MEDLINE</source><source>SpringerLink_现刊</source><creator>Watanabe, Gina ; Young, Kurtis ; Rauber, Erin ; Khan, Mohammad Faizan ; Suzuki, Reannon ; Riestenberg, Robert ; Umana, Giuseppe E. ; Palmisciano, Paolo</creator><creatorcontrib>Watanabe, Gina ; Young, Kurtis ; Rauber, Erin ; Khan, Mohammad Faizan ; Suzuki, Reannon ; Riestenberg, Robert ; Umana, Giuseppe E. ; Palmisciano, Paolo</creatorcontrib><description>Purpose
Extraneural meningioma metastasis is a rare occurrence and may pose a clinical challenge due to its unclear prognosis. In this systematic review, we analyze patient demographics, clinical characteristics, management strategies, and outcomes.
Methods
PubMed, EMBASE, Scopus, Cochrane, and Web of Science databases were searched from inception to February 23, 2024 for cases of metastatic meningioma according to PRISMA guidelines. Descriptive statistics, Mann–Whitney U test, Fisher's exact tests, Kaplan–Meier curves, and log-rank tests were used for selected analyses.
Results
A total of 288 patients (52% male) were included with an average age of 49 years at meningioma diagnosis. Tumors were distributed across WHO grade 1 (38%), 2 (36%), and 3 (26%). Most patients experienced intracranial recurrence (79%) and mean time to first metastasis was approximately 8 years. No change in WHO grade between primary and metastasis was observed for most cases (65%). Treatment of the initial metastasis was most often with surgery (43%), chemotherapy (20%), or no treatment (14%). Half of the patients were alive (50%) with an average follow-up of 3 years following metastasis. Overall median survival was 36 months for the entire cohort. This differed significantly between WHO grade 1 versus 2/3 meningioma primaries (168 vs. 15 months, p < 0.005).
Conclusion
Metastatic meningioma appears to be associated with more positive prognosis than other brain tumor types with extra-neural metastasis or metastasis in general. This is particularly true for cases arising from a WHO grade 1 meningioma.</description><identifier>ISSN: 0167-594X</identifier><identifier>ISSN: 1573-7373</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-024-04659-6</identifier><identifier>PMID: 38530549</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Brain cancer ; Brain tumors ; Chemotherapy ; Humans ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Meningeal Neoplasms - pathology ; Meningeal Neoplasms - secondary ; Meningeal Neoplasms - therapy ; Meningioma ; Meningioma - pathology ; Meningioma - therapy ; Metastases ; Metastasis ; Middle Aged ; Neurology ; Oncology ; Patients ; Prognosis ; Review ; Systematic review</subject><ispartof>Journal of neuro-oncology, 2024-06, Vol.168 (2), p.187-196</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-148d17ac0ccc7a9166f89d8895861e52ac3445318f84247d50c782180be22b663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-024-04659-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-024-04659-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38530549$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Watanabe, Gina</creatorcontrib><creatorcontrib>Young, Kurtis</creatorcontrib><creatorcontrib>Rauber, Erin</creatorcontrib><creatorcontrib>Khan, Mohammad Faizan</creatorcontrib><creatorcontrib>Suzuki, Reannon</creatorcontrib><creatorcontrib>Riestenberg, Robert</creatorcontrib><creatorcontrib>Umana, Giuseppe E.</creatorcontrib><creatorcontrib>Palmisciano, Paolo</creatorcontrib><title>A systematic review of extraneural meningioma metastasis: timing, evolution and outlook</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
Extraneural meningioma metastasis is a rare occurrence and may pose a clinical challenge due to its unclear prognosis. In this systematic review, we analyze patient demographics, clinical characteristics, management strategies, and outcomes.
Methods
PubMed, EMBASE, Scopus, Cochrane, and Web of Science databases were searched from inception to February 23, 2024 for cases of metastatic meningioma according to PRISMA guidelines. Descriptive statistics, Mann–Whitney U test, Fisher's exact tests, Kaplan–Meier curves, and log-rank tests were used for selected analyses.
Results
A total of 288 patients (52% male) were included with an average age of 49 years at meningioma diagnosis. Tumors were distributed across WHO grade 1 (38%), 2 (36%), and 3 (26%). Most patients experienced intracranial recurrence (79%) and mean time to first metastasis was approximately 8 years. No change in WHO grade between primary and metastasis was observed for most cases (65%). Treatment of the initial metastasis was most often with surgery (43%), chemotherapy (20%), or no treatment (14%). Half of the patients were alive (50%) with an average follow-up of 3 years following metastasis. Overall median survival was 36 months for the entire cohort. This differed significantly between WHO grade 1 versus 2/3 meningioma primaries (168 vs. 15 months, p < 0.005).
Conclusion
Metastatic meningioma appears to be associated with more positive prognosis than other brain tumor types with extra-neural metastasis or metastasis in general. This is particularly true for cases arising from a WHO grade 1 meningioma.</description><subject>Brain cancer</subject><subject>Brain tumors</subject><subject>Chemotherapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meningeal Neoplasms - pathology</subject><subject>Meningeal Neoplasms - secondary</subject><subject>Meningeal Neoplasms - therapy</subject><subject>Meningioma</subject><subject>Meningioma - pathology</subject><subject>Meningioma - therapy</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Review</subject><subject>Systematic review</subject><issn>0167-594X</issn><issn>1573-7373</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFTEUhoNU7G31D7goATdddPTkO3FXLtoKBTeK7kJuJlPSzkzaJNPaf2-ut1ZwUQgkJE_e8_Ig9JbAewKgPhRCQEIHlHfApTCdfIFWRCjWKabYHloBkaoThv_cRwelXAEAV4y8QvtMCwaCmxX6cYrLQ6lhcjV6nMNdDPc4DTj8qtnNYcluxFOY43wZ0-TasbrSViwfcY1Tuz7B4S6NS41pxm7ucVrqmNL1a_RycGMJbx73Q_T986dv6_Pu4uvZl_XpRecZlbUjXPdEOQ_ee-UMkXLQptfaCC1JENR5xrlgRA-aU656AV5pSjRsAqUbKdkhOt7l3uR0u4RS7RSLD-PYyqelWAbAODOak4a--w-9SkueW7tGSWaoJMI0iu4on1MpOQz2JsfJ5QdLwG61251227TbP9rttsXRY_SymUL_9OWv5wawHVDa03wZ8r_Zz8T-Bt9CjJs</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Watanabe, Gina</creator><creator>Young, Kurtis</creator><creator>Rauber, Erin</creator><creator>Khan, Mohammad Faizan</creator><creator>Suzuki, Reannon</creator><creator>Riestenberg, Robert</creator><creator>Umana, Giuseppe E.</creator><creator>Palmisciano, Paolo</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>A systematic review of extraneural meningioma metastasis: timing, evolution and outlook</title><author>Watanabe, Gina ; Young, Kurtis ; Rauber, Erin ; Khan, Mohammad Faizan ; Suzuki, Reannon ; Riestenberg, Robert ; Umana, Giuseppe E. ; Palmisciano, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-148d17ac0ccc7a9166f89d8895861e52ac3445318f84247d50c782180be22b663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Brain cancer</topic><topic>Brain tumors</topic><topic>Chemotherapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meningeal Neoplasms - pathology</topic><topic>Meningeal Neoplasms - secondary</topic><topic>Meningeal Neoplasms - therapy</topic><topic>Meningioma</topic><topic>Meningioma - pathology</topic><topic>Meningioma - therapy</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Review</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Watanabe, Gina</creatorcontrib><creatorcontrib>Young, Kurtis</creatorcontrib><creatorcontrib>Rauber, Erin</creatorcontrib><creatorcontrib>Khan, Mohammad Faizan</creatorcontrib><creatorcontrib>Suzuki, Reannon</creatorcontrib><creatorcontrib>Riestenberg, Robert</creatorcontrib><creatorcontrib>Umana, Giuseppe E.</creatorcontrib><creatorcontrib>Palmisciano, Paolo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Watanabe, Gina</au><au>Young, Kurtis</au><au>Rauber, Erin</au><au>Khan, Mohammad Faizan</au><au>Suzuki, Reannon</au><au>Riestenberg, Robert</au><au>Umana, Giuseppe E.</au><au>Palmisciano, Paolo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A systematic review of extraneural meningioma metastasis: timing, evolution and outlook</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>168</volume><issue>2</issue><spage>187</spage><epage>196</epage><pages>187-196</pages><issn>0167-594X</issn><issn>1573-7373</issn><eissn>1573-7373</eissn><abstract>Purpose
Extraneural meningioma metastasis is a rare occurrence and may pose a clinical challenge due to its unclear prognosis. In this systematic review, we analyze patient demographics, clinical characteristics, management strategies, and outcomes.
Methods
PubMed, EMBASE, Scopus, Cochrane, and Web of Science databases were searched from inception to February 23, 2024 for cases of metastatic meningioma according to PRISMA guidelines. Descriptive statistics, Mann–Whitney U test, Fisher's exact tests, Kaplan–Meier curves, and log-rank tests were used for selected analyses.
Results
A total of 288 patients (52% male) were included with an average age of 49 years at meningioma diagnosis. Tumors were distributed across WHO grade 1 (38%), 2 (36%), and 3 (26%). Most patients experienced intracranial recurrence (79%) and mean time to first metastasis was approximately 8 years. No change in WHO grade between primary and metastasis was observed for most cases (65%). Treatment of the initial metastasis was most often with surgery (43%), chemotherapy (20%), or no treatment (14%). Half of the patients were alive (50%) with an average follow-up of 3 years following metastasis. Overall median survival was 36 months for the entire cohort. This differed significantly between WHO grade 1 versus 2/3 meningioma primaries (168 vs. 15 months, p < 0.005).
Conclusion
Metastatic meningioma appears to be associated with more positive prognosis than other brain tumor types with extra-neural metastasis or metastasis in general. This is particularly true for cases arising from a WHO grade 1 meningioma.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>38530549</pmid><doi>10.1007/s11060-024-04659-6</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2024-06, Vol.168 (2), p.187-196 |
| issn | 0167-594X 1573-7373 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3003439841 |
| source | MEDLINE; SpringerLink_现刊 |
| subjects | Brain cancer Brain tumors Chemotherapy Humans Male Medical prognosis Medicine Medicine & Public Health Meningeal Neoplasms - pathology Meningeal Neoplasms - secondary Meningeal Neoplasms - therapy Meningioma Meningioma - pathology Meningioma - therapy Metastases Metastasis Middle Aged Neurology Oncology Patients Prognosis Review Systematic review |
| title | A systematic review of extraneural meningioma metastasis: timing, evolution and outlook |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A49%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20systematic%20review%20of%20extraneural%20meningioma%20metastasis:%20timing,%20evolution%20and%20outlook&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Watanabe,%20Gina&rft.date=2024-06-01&rft.volume=168&rft.issue=2&rft.spage=187&rft.epage=196&rft.pages=187-196&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-024-04659-6&rft_dat=%3Cproquest_cross%3E3003439841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3063926159&rft_id=info:pmid/38530549&rfr_iscdi=true |